LOS ANGELES, April 17, 2019 (GLOBE NEWSWIRE) -- PRESS RELEASE -- OG DNA Genetics, a global cannabis brand, has announced that the company has entered into an agreement with Good Meds to bring DNA’s award-winning team to the Colorado marketplace for the first time. The partnership will provide Colorado cannabis consumers access to the DNA brand and library of proprietary genetics, flower and concentrates at Good Meds facilities in Lakewood and Englewood, Colorado.
“Colorado was the pioneer in the legalization of cannabis in the U.S., but it has faced challenges in producing and delivering connoisseur level cannabis products to the state’s consumers,” said Charles Phillips, CEO of OG DNA Genetics. “We are excited to certify our award-winning strains to the state and by the opportunities this agreement will provide to further grow our footprint. Good Meds has a strong commitment to bringing products to market with a focus on quality, which is why we have selected them as our partner.”
As part of the partnership with Good Meds, DNA will verify and certify its award-winning genetics and utilize Good Meds experienced team and commitment to quality to offer an array of products to the Colorado market, including dried flower, prerolls, vape carts, sauce, rosin and full melt water hash. The partnership will also provide DNA access to BOSM Labs for its cutting-edge hydrocarbon extract technology as well as future research and product development.
“The cannabis industry in Colorado has evolved much differently than other markets, one example of this, we are lacking globally recognized brands. DNA will bring this,” said John Knapp, founder and CEO of Good Meds and BOSM Labs. “Our 90,000-square-foot production facility that is BOSM Labs and Good Meds is an ideal platform for DNA to begin their entrance into the first fully legal cannabis market in the world. We are absolutely thrilled about the partnership and excited to introduce their suite of top tier products into the marketplace.”
